ロード中...
Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon EGFR L861Q and G719X Mutations
Background: In the majority of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations, first generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are ineffective. The second-generation TKI, afatinib, is considered effective in patients with uncommon mu...
保存先:
| 出版年: | In Vivo |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
International Institute of Anticancer Research
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7279823/ https://ncbi.nlm.nih.gov/pubmed/32354946 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11929 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|